
Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. (ELTX)
WebsitePrice
Market cap
Next catalystExpected Q4 2026Camupepimut + daraxonrasib, with or without nivolumab — planned metastatic PDAC study · Trial initiationSEC filing ↗
Cash
Chart & Events
Core Clinical
PreINDP1P2P3FilingApproved
camupepimutCamupepimut + daraxonrasib, with or without nivolumab — planned metastatic PDAC study
KRAS G12D × KRAS G12R × KRAS G12V × KRAS G12C × KRAS G12A × KRAS G12S × KRAS G13D
PreINDP2P3FilingApproved
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Representative pipeline applications
Clinical
Upcoming clinical milestones
camupepimutCamupepimut + daraxonrasib, with or without nivolumab — planned metastatic PDAC study
KRAS G12D × KRAS G12R × KRAS G12V × KRAS G12C × KRAS G12A × KRAS G12S × KRAS G13D
PreINDP2P3FilingApproved
PreINDP1P2P3FilingApproved
Other pipelines
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Partner / License out
PreINDP1P2P3FilingApproved